Efficacy of low-dose Proton Pump Inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan

Hepato-Gastroenterology

Volumn 54, Issue 74, 2007, Pages 649-654

  Kawai, Takashi ^a,d   Kawakami, Kohei ^a   Mikinori, Kataoka ^b   Takei, Kazuo ^b   Itoi, Takao ^b   Moriyasu, Fuminori ^b   Takagi, Yuu ^b   Aoki, Tatsuya ^b   Watanebe, Kiyoshi ^c   Matsumoto, Yuushuke ^c   Rimbara, Emiko ^c   Noguchi, Norihisa ^c   Sasatsu, Masanori ^c  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d NONE   (Japan)

Author keywords

Eradication; Helicobacter pylori; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOATING; BLOCKED EAR; CHEILOSIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EAR DISEASE; ERADICATION THERAPY; EYELID EDEMA; FEMALE; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; JAPAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHENOTYPE; PRIORITY JOURNAL; RASH; TASTE DISORDER; TREATMENT RESPONSE; URTICARIA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHENOTYPE; POLYMORPHISM, GENETIC; PROTON PUMPS; RETREATMENT; STOMACH DISEASES; TREATMENT OUTCOME;

EID: 34248144817     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Marshal GJ, Warren JR: Unidentified curved bacilli in the stomach of patient with gastritis and peptic ulceration. Lancet 1984; 1i:1311-1314.
2. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, Festen HP, Meuwissen SG: Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345:1525-1528).
3. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ: Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325:1132-1136.
4. Wotherspoon AC, Doglioni C, de Boni M, Spencer J, Isaacson PG: Antibiotic treatment for low-grade gastric MALT lymphoma. Lancet 1994; 343:1098-1099.
5. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127-1131.
6. Uemura N, Okamoto S, Yamamoto S Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345:784-789.
7. Asaka M, Satoh K, Sugano K, Sugiyama T, Takahashi S, Fukuda Y, Ota H, Murakami K, Kimura K, Shimoyama T: Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001; 6:177-186.
8. Marshall BJ, Godwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, Philips M, Waters TE, Sanderson CR: Prospective, double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2:1437-1442.
9. Borody T, Cole P, Noonan S, Morgan A, Lenne J, Hyland L, Brandl S, Borody EG, George LL: Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989; 151:431-435.
10. Fujioka T, Uribe RU, Kubota T, Murakami K, Kawasaki H, Nasu M: Peptic ulcer recurrence after Helicobacter pylori eradication: a 5-year follow up study. Eur J Gastroenterol 1995; 7(Suppl 1):S35-38.
11. Asaka M, Kato M, Sugiyama M, Satoh K, Kuwayama H, Fukuds Y, Fujioka T, Takemoto T, Kimura K, Shimoyama T, Shimizu K, Kobayashi S, Japan Helicobacter pylori Eradication Study Group: Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol 2003; 38:339-347.
12. Miwa H, Sakaki N, Sugano, Sekine H, Higuchi K, Uemura N, Kato M, Murakami K, Kato C, Shiotani A, Ohkusa T, Takagi A, Aoyama N, Haruma K, Okazaki K, Kusugami K, Suzuki M, Joh T, Azuma T, Yanaka A, Suzuki H, Hashimoto H, Kawai T, Sugiyama T: Recurrence peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter 2004; 9:9-16.
13. Bazzoli F, Pozzato P, Zagari M, Fossi S, Ricciardiello L, Nicolini G, Berretti D, DeLuca L: Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. Helicobacter 1998; 3:195-201.
14. Asaka M, Sugiyama T, Kato M, Satoh K, Kuwayama H, Fukuda Y, Fujoka T, Takemoto T, Kimura K, Shimoyama T, Shimizu K, Kobayashi S: A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001; 6:254-261.
15. Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S, Watanabe S, Sato N: Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection: comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13:741-746.
16. Miwa H, Yamada T, Sato K, Ohta K, Okura R, Murai T, Nagahara A, Takei Y, Ogihara T, Sato N: Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection. Comparison of 20 mg and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci 2000; 45:77-82.
17. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobila Susceptibility Testing; Twelfth Informational Supplement. M100-S12. Viillanova, PA: NCCLS, 2002.
18. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269:15419-15422.
19. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46:594-598.
20. Hokari K, Sugiyama T, Kato M, Sato M, Miyagishima T, Kudo M, Nishikawa K, Ishizuka J, Komatsu Y, Mizushima T, Kagaya H, Takeda H, Asaka M: Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 2001; 15:1479-1484.
21. Perri F, Villani MR, Festa V, Quitafdamo M, Andriulli A: Predictors f failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001; 15:1023-1029.
22. Kamada T, Haruma K, Komoto K, Mihara M, Chen X, Yoshihara M, Sumii K, Kajiyama G, Tahara K, Kawamura Y: Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin and clarithromycin. Helicobacter 1999; 4:204-210.
23. Kamada T, Haruma K, Miyoshi E, Mihara M, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G, Tahara K, Murai T, Kawamura Y, Hattori N: Cetraxate, a mucosal protective agent, combined with omeprazole, amoxicillin and clarithromycin increases the eradication rate of Helicobacter pylori in smokers. Aliment Pharmacol Ther 2000; 14:1089-1094.
24. Furuta T, Naohito S, Takashima, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishuzaki T, Kaneko E: Effect of genotypic difference in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Pharmacogenet Genomics Clin Pharmacol Ther 2001; 69:158-168.
25. Poon SK, Chang CS, SU J, Lai CH, Yang CC, Chen GH, Wang WC: Primary resistance to antibiotics and its clinical impact the efficacy of Helicobacter pylori lansoprazole-based triple therapy. Aliment Pharmacol Ther 2002; 16:291-296.
26. Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N: Clarithromycin resistance, but not CYP2C19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for the cure of H. pylori infection. Dig Dis Sci 2001; 46:2445-2450.
27. Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T: Randomized open trial comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. Helicobacter pylori infection: CYP2C19 genotype and serum ferritin. J Gastroenterol Hepatol 2002; 17:748-753.
28. Sachs G, Meyer-Rosberg K, Scott DR, Melhers K, Shin J, Besancon M: Acid secretion and Helicobacter pylori. Digestion 1997; 58(Suppl 1):8-13.
29. Ishizaki T, Horai Y: Cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole (Review Article). Aliment Pharmacol Ther 1999; 13(Suppl 3):27-36.
30. Saito T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S: Effects of rabeprazole, lansoprazole and omerpazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16:1811-1817.
31. Perez Aldana L, Kato M, Nakagawa S, Kawarasaki M, Nagasako T, Mizushiuma T, Oda H, Kodaira J, Shimizu Y, Komatsu Y, Zheng R, Takeda H, Sugiyama T, Asaka M: The relationship between consumption of antimicrobial agents and prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7:306-309.
32. Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M: Drug combinations with the amoxicillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002; 19:67-70.
33. Debets-Ossenkopp YJ, Sparrius M, Kuster JG, Kolkman JJ, Vandenbroucke-Grauls CM: Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett 1996; 142:37-42.
34. Versalvoic J, Shortrige D, Kriber K, Griffy MV, Beyer J, Flamm RK, Tanaka SK, Graham DY, Go MF: Mutations in 235 rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40:477-480.
35. Kawai T, Kawakami K, Kudo T, Takei K, Moriyasu F, Takagi Y, Aoki T, Koyanagi Y, Serizawa H, Rinbara E, Noguchi M, Sasatsu M: Resistance to antimicrobial agents in eradication of Helicobacter pylori infection. Ann Cancer Res Ther 2003; 11:129-142.
36. Kaneko F, Suzuki H, Hasegawa N,Kurabayashi K, Saito H, Otani S, Nakamizo H, Kawata K, Miyairi M, Ishii K, Ishii H: High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. Aliment Pharmacol Ther 2004; 20(Suppl):62-67.
37. Murakami K, Sato R, Okimoto T, Nasu M, Fijioka T, Kodama M, Kagawa J, Sato S, Abe H, Arita T: Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-lone Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003; 17:119-123.
38. Tankovic J, Lamarque D, Lascols C, Soussy CJ, Delchier JC: Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Aliment Pharmacol Ther 2001; 15:707-713.
39. Hoshiya S, Watanabe K, Tokunaga K, Tanaka A, Ninomya H, Shingaki M, Ito T, Saito S, Ishida H, Takahasi S: Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J Gastroenterol 2000; 35:10-14.
40. Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kobayashi M, Oyasu K, Hayakumo T, Mizuno S, Kiyota K, Nakajima M, Kimoto K, Inokuchi H, Kawai K: Effect of different proton pump inhibitor, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003; 17:259-264.
41. Nakamura M, Spiller RC, Barrett DA, Wibawa JI, Kumagai N, Tuschimoto K, Tanaka T: Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy. Helicobacter 2003; 4:294-299.
42. Ohara T, Goshi S, Taneike I, Tamura Y, Zhang HM, Yamamoto T: Inhibitory action of a novel proton pump inhibitor, rabeprale, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter 2001; 6:125-129.